Eli Lilly and Company

Leonard Larry Winneroski, Jr

Yanping Xu

Margaret Mary Faul

Brian Morgan Watson

Dustin James Mergott

Steven James Green

Michael R Jirousek

Owen Brendan Wallace

Samuel James Dominianni

Jose Eduardo Lopez

Alexander Glenn Godfrey

Dawn Alisa Brooks

Thomas Edward Mabry

Christopher J Rito

Nancy June Snyder

Yuan Shi

James R McCarthy

Alan M Warshawsky

Thomas Daniel Aicher

Russell Dean Stucky

Guoxin Zhu

Nathan Bryan Mantlo

Scott Eugene Conner

Erik James Hembre, Ii

Daryl Lynn Smith

Lynn Stacy Gossett

Renhua Li

Gary Lowell Engel

Lori Ann Richardson

Nagy Alphonse Farid

Sarah Beth Jones

Matthew Joseph Fisher

Timothy Paul Burkholder

Joseph P Burkhart

Warren Jaye Porter

Ronald Jay Hinklin

Jefferson Ray McCowan

Jeremy Schulenburg York

James Peter Beck

Shawn Christopher Miller

Karin Briner

Brian Michael Mathes

Zhaogen Chen

Jeffrey Thomas Mullaney

Xiaodong Wang

Zoran Rankovic

Nicolas Jacques Francois Dreyfus

Matthew Robert Reinhard

William Harlan Gritton

Ashraf Saeed

Hongqi Tian

Allie Edward Tripp

Alexei Pavlovych Krasutsky

Brian Eugene Cunningham

Eric Michael Woerly

Donald Paul Matthews

Mark Joseph Chicarelli

Robert J Ardecky

Yao-Chang Xu

Cynthia Darshini Jesudason

John Gordon Allen

Richard Craig Thompson

Dennis C Thompson

John S Tyhonas

Peter Biagio Anzeveno

Winton Dennis Jones, Jr

Richard Duane Johnston

Daniel Ray Mayhugh

Freddie Craig Stevens

Timothy Andrew Woods

Jonathan Edward Green

Roger Ryan Rothhaar

Gary A Hite

James Lee Toth

Jennifer Anne McMahon

Simon James Richards

Francis O Ginah

Frank Brown, Jr

Jennifer Ann Vance

Pierre Yves Michellys

Christopher John Rit

Christine Ann Krumrich

Tracey Ann Gibson

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.

(Trifluoromethyl)pyrimidine-2-amine compounds

The present invention provides a compound of Formula I:  

(trifluoromethyl)pyrimidine-2-amine compounds

The present invention provides a compound of Formula I:  or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.

6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof, that are inhibitors of BACE.

Selective BACE1 inhibitors

The present invention provides a compound of Formula III:  

BACE inhibitors

The present invention provides a compound of Formula III: Formula III 

The present invention provides a compound of Formula I:  or a pharmaceutically acceptable salt thereof.

Tetrahydropyrrolothiazine compounds

The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; Ris H or F;Ris H, &#x2014;CHOH, C1-C3 alkyl, Ris H, F, or CN;Ris H, F; or CN; andRis H, &#x2014;CH, or &#x2014;OCH;or a pharmaceutically acceptable salt thereof.

The present invention provides a compound of Formula I: Formula I or a pharmaceutically acceptable salt thereof.

The present invention provides compounds of Formula I: wherein A is selected from the group consisting of;  

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 Beta-HSD type 1 activity. X-17377

Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Growing community of inventors

Greenwood, IN, United States of America

Leonard Larry Winneroski, Jr